BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent

Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

UN race committee says global north’s COVID-19 IP position violates human rights

5 September 2023 UN Committee on Racial Discrimination Calls for equitable access to vaccines, treatments, and health tech | Switzerland, Germany, UK, and US refusal to waive IP rights for COVID-19 vaccines 'aids discrimination against vulnerable communities'.

Big Pharma

Moderna, Pfizer and BioNTech hit with COVID-19 vaccine lawsuits over mRNA tech

8 June 2023 Promosome claimed it shared mRNA tech with the trio, who went on to make hugely successful vaccines | The small biotech wants a cut of more than $100 billion allegedly made by the big pharma companies.

Biotechnology

Pfizer faces infringement suit over COVID-19 vaccine

6 April 2023 Arbutus and Genevant claims Pfizer/BioNTech vaccine uses patented technology | Claim follows last year’s lawsuit against Moderna.